23andMe's Uncertain Future
This is a news story, published by Wired, that relates primarily to Anne Wojcicki news.
Anne Wojcicki news
For more Anne Wojcicki news, you can click here:
more Anne Wojcicki newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsWired news
For more news from Wired, you can click here:
more news from WiredAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
genetic testing company. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest 23andMe kits news, health tech investor news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
23andMe mean consumer geneticsWired
•23andMe Is Sinking Fast. Can the Company Survive?
76% Informative
23andMe has been in free fall since a major data breach last year that affected roughly half of its customers.
The company has tried to keep customers coming back with a premium service that provides more genetic reports, personalized health recommendations, and historical relative matches.
CEO Anne Wojcicki had said she would consider third -party takeover offers.
23andMe recently shut down its drug discovery unit, but it is continuing to advance the drug candidates it already has in clinical trials.
In 2021 , it acquired telehealth service Lemonaid , which started offering Ozempic, Wegovy , and compounded semaglutide in August .
Estelle Giraud , CEO and founder of Trellis Health , says the anti-obesity space is already crowded.
VR Score
72
Informative language
69
Neutral language
31
Article tone
informal
Language
English
Language complexity
47
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
9
Source diversity
5
Affiliate links
no affiliate links